Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors
2016-01-01 Savastano, B; Della Corte, Cm; Papaccio, F; Giuseppe, V; Esposito, G; Fasano, M; Orditura, M; De Vita, F; Ciardiello, F; Morgillo, F
Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites
2018-01-01 Morgillo, F; Della Corte, Cm; Viscardi, G; Di Liello, R; Papaccio, F; Ciardiello, F
ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition
2019-01-01 Valiente, Fg; Tarazona, N; Gambardella, V; Riffo-Campos, A; Papaccio, F; Cabeza-Segura, M; López-Rodas, G; Cervantes, A; Franco, L; Castillo, J
Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistence
2016-01-01 Esposito, G; Della Corte, Cm; Papaccio, F; Viscardi, G; Fasano, M; Troiani, T; Martinelli, E; Ciardiello, F; Morgillo, F
Met/Axl system as a dual target in the mesothelioma pathway and invasiveness
2017-01-01 Viscardi, G; Ciaramella, V; Della Corte, Cm; Papaccio, F; Esposito, G; Di Liello, R; Troiani, T; Orditura, M; Ciardiello, F; Morgillo, F
Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor
2020-01-01 Papaccio, F; Bravo, Mfg; Cabeza-Segura, M; Gimeno-Valiente, F; Gambardella, V; Garzón-Lloría, Z; García-Micó, B; Huerta, M; Martínez-Ciarpaglini, C; Alfaro-Cervello, C; Sabater, L; Lombardi, P; Rentero-Garrido, P; Zúñiga-Trejos, S; Keränen, Sr; Fleitas, T; Tarazona, N; Roda, D; Cervantes, A; Castillo, J
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSLC cancer: a preliminary study to identify biomarkers of efficacy
2017-01-01 Barra, G; Pasquale, G; Della Corte, C; Papaccio, F; Ciardiello, F; Morgillo, F; De Palma, R
A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC
2019-01-01 Viscardi, G; Sparano, F; Di Liello, R; Casal, Ga; Ferreres, Rb; Bruixola, G; Gambardella, V; Zanaletti, N; Iacovino, Ml; Della Corte, Cm; Papaccio, F; Fasano, M; Ciardiello, F; Cervantes, A; Morgillo, F; Martorell, Pm; Molla, Mai
Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations
2016-01-01 Viscardi, G; Della Corte, Cm; Papaccio, F; Esposito, G; Fasano, M; Martinelli, E; Troiani, T; Ciardiello, F; Morgillo, F
An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models
2020-01-01 Gambardella, V; Gimeno-Valiente, F; Cabeza, M; Papaccio, F; Zúñiga-Trejos, S; Carbonell-Asins, Ja; Rentero-Garrido, P; Huerta, M; Keränen, Sr; Cejalvo, Jm; Roda, D; Tarazona, N; Fleitas, T; Cervantes, A; Castillo, J
3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients
2020-01-01 Cabeza, M; Papaccio, F; Bravo, Mfg; Gambardella, V; Alfaro-Cervello, C; Martínez-Ciarpaglini, C; Garzón-Lloría, Z; Rentero-Garrido, P; Zúñiga-Trejos, S; Seda-García, E; Gimeno-Valiente, F; Peña, A; Barrios, M; Tarazona, N; Roda, D; Cervantes, A; Fleitas, T; Castillo, J
Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance
2016-01-01 Papaccio, F; Della Corte, Cm; Viscardi, G; Esposito, G; Fasano, M; De Vita, F; Orditura, M; Ciardiello, F; Morgillo, F
Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC)
2017-01-01 Bruixola, G; Caballero, J; Papaccio, F; Petrillo, A; Pastor, M; Cervantes, A
Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites
2017-01-01 Della Corte, Cm; Barra, G; Ciaramella, V; Papaccio, F; Viscardi, G; Esposito, G; Di Liello, R; Orditura, M; Troiani, T; De Palma, R; Ciardiello, F; Morgillo, F
Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial
2016-01-01 Fasano, M; Della Corte, Cm; Papaccio, F; Viscardi, G; Esposito, G; Troiani, T; Martinelli, E; Ciardiello, F; Morgillo, F
CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations
2019-01-01 Papaccio, F; Valiente, Fg; Gutierrez-Bravo, Mf; Cabeza-Segura, M; Gambardella, V; Huerta, Mds; Martinez-Ciarpaglini, C; Alfaro-Cervello, C; Rentero-Garrido, P; Zúñiga-Trejos, S; Keranen, Sr; Fleitas, T; Tarazona, N; Perez, Dr; Cervantes, A; Castillo, J
Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype
2019-01-01 Llavero, Nt; Gimeno-Valiente, F; Gambardella, V; Huerta, M; Keranen, Sr; Bruixola, G; Fontana, E; Ciarpaglini, Cm; Zuñiga, S; Rentero, P; Fleitas, T; Papaccio, F; Moro, D; Pla, V; Nyamundanda, G; Castillo, J; Sadanadam, A; Espí, A; Roda, D; Cervantes, A
Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models
2018-01-01 Morgillo, F; Della Corte, Cm; Alfieri, R; Petronini, P; La Monica, S; Papaccio, F; Ciardiello, F
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: a preliminary study to identify biomarkers of efficacy
2016-01-01 Barra, G; Pasquale, G; Della Corte, Cm; Papaccio, F; Orditura, M; Devita, F; Ciardiello, F; De Palma, R; Morgillo, F
Patient-derived organoids as a tool for modelling localized colorectal cancer
2020-01-01 Bravo, Mfg; Papaccio, F; Cabeza, M; Martínez-Ciarpaglini, C; Alfaro-Cervello, C; Garzón-Lloría, Z; Ferrer-Martínez, A; García-Micó, B; Gambardella, V; Rentero-Garrido, P; Fleitas, T; Moro-Valdezate, D; Huerta, M; Tarazona, N; Roda, D; Cervantes, A; Castillo, J
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors | 1-gen-2016 | Savastano, B; Della Corte, Cm; Papaccio, F; Giuseppe, V; Esposito, G; Fasano, M; Orditura, M; De Vita, F; Ciardiello, F; Morgillo, F | |
Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites | 1-gen-2018 | Morgillo, F; Della Corte, Cm; Viscardi, G; Di Liello, R; Papaccio, F; Ciardiello, F | |
ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition | 1-gen-2019 | Valiente, Fg; Tarazona, N; Gambardella, V; Riffo-Campos, A; Papaccio, F; Cabeza-Segura, M; López-Rodas, G; Cervantes, A; Franco, L; Castillo, J | |
Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistence | 1-gen-2016 | Esposito, G; Della Corte, Cm; Papaccio, F; Viscardi, G; Fasano, M; Troiani, T; Martinelli, E; Ciardiello, F; Morgillo, F | |
Met/Axl system as a dual target in the mesothelioma pathway and invasiveness | 1-gen-2017 | Viscardi, G; Ciaramella, V; Della Corte, Cm; Papaccio, F; Esposito, G; Di Liello, R; Troiani, T; Orditura, M; Ciardiello, F; Morgillo, F | |
Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor | 1-gen-2020 | Papaccio, F; Bravo, Mfg; Cabeza-Segura, M; Gimeno-Valiente, F; Gambardella, V; Garzón-Lloría, Z; García-Micó, B; Huerta, M; Martínez-Ciarpaglini, C; Alfaro-Cervello, C; Sabater, L; Lombardi, P; Rentero-Garrido, P; Zúñiga-Trejos, S; Keränen, Sr; Fleitas, T; Tarazona, N; Roda, D; Cervantes, A; Castillo, J | |
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSLC cancer: a preliminary study to identify biomarkers of efficacy | 1-gen-2017 | Barra, G; Pasquale, G; Della Corte, C; Papaccio, F; Ciardiello, F; Morgillo, F; De Palma, R | |
A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC | 1-gen-2019 | Viscardi, G; Sparano, F; Di Liello, R; Casal, Ga; Ferreres, Rb; Bruixola, G; Gambardella, V; Zanaletti, N; Iacovino, Ml; Della Corte, Cm; Papaccio, F; Fasano, M; Ciardiello, F; Cervantes, A; Morgillo, F; Martorell, Pm; Molla, Mai | |
Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations | 1-gen-2016 | Viscardi, G; Della Corte, Cm; Papaccio, F; Esposito, G; Fasano, M; Martinelli, E; Troiani, T; Ciardiello, F; Morgillo, F | |
An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models | 1-gen-2020 | Gambardella, V; Gimeno-Valiente, F; Cabeza, M; Papaccio, F; Zúñiga-Trejos, S; Carbonell-Asins, Ja; Rentero-Garrido, P; Huerta, M; Keränen, Sr; Cejalvo, Jm; Roda, D; Tarazona, N; Fleitas, T; Cervantes, A; Castillo, J | |
3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients | 1-gen-2020 | Cabeza, M; Papaccio, F; Bravo, Mfg; Gambardella, V; Alfaro-Cervello, C; Martínez-Ciarpaglini, C; Garzón-Lloría, Z; Rentero-Garrido, P; Zúñiga-Trejos, S; Seda-García, E; Gimeno-Valiente, F; Peña, A; Barrios, M; Tarazona, N; Roda, D; Cervantes, A; Fleitas, T; Castillo, J | |
Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance | 1-gen-2016 | Papaccio, F; Della Corte, Cm; Viscardi, G; Esposito, G; Fasano, M; De Vita, F; Orditura, M; Ciardiello, F; Morgillo, F | |
Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC) | 1-gen-2017 | Bruixola, G; Caballero, J; Papaccio, F; Petrillo, A; Pastor, M; Cervantes, A | |
Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites | 1-gen-2017 | Della Corte, Cm; Barra, G; Ciaramella, V; Papaccio, F; Viscardi, G; Esposito, G; Di Liello, R; Orditura, M; Troiani, T; De Palma, R; Ciardiello, F; Morgillo, F | |
Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial | 1-gen-2016 | Fasano, M; Della Corte, Cm; Papaccio, F; Viscardi, G; Esposito, G; Troiani, T; Martinelli, E; Ciardiello, F; Morgillo, F | |
CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations | 1-gen-2019 | Papaccio, F; Valiente, Fg; Gutierrez-Bravo, Mf; Cabeza-Segura, M; Gambardella, V; Huerta, Mds; Martinez-Ciarpaglini, C; Alfaro-Cervello, C; Rentero-Garrido, P; Zúñiga-Trejos, S; Keranen, Sr; Fleitas, T; Tarazona, N; Perez, Dr; Cervantes, A; Castillo, J | |
Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype | 1-gen-2019 | Llavero, Nt; Gimeno-Valiente, F; Gambardella, V; Huerta, M; Keranen, Sr; Bruixola, G; Fontana, E; Ciarpaglini, Cm; Zuñiga, S; Rentero, P; Fleitas, T; Papaccio, F; Moro, D; Pla, V; Nyamundanda, G; Castillo, J; Sadanadam, A; Espí, A; Roda, D; Cervantes, A | |
Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models | 1-gen-2018 | Morgillo, F; Della Corte, Cm; Alfieri, R; Petronini, P; La Monica, S; Papaccio, F; Ciardiello, F | |
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: a preliminary study to identify biomarkers of efficacy | 1-gen-2016 | Barra, G; Pasquale, G; Della Corte, Cm; Papaccio, F; Orditura, M; Devita, F; Ciardiello, F; De Palma, R; Morgillo, F | |
Patient-derived organoids as a tool for modelling localized colorectal cancer | 1-gen-2020 | Bravo, Mfg; Papaccio, F; Cabeza, M; Martínez-Ciarpaglini, C; Alfaro-Cervello, C; Garzón-Lloría, Z; Ferrer-Martínez, A; García-Micó, B; Gambardella, V; Rentero-Garrido, P; Fleitas, T; Moro-Valdezate, D; Huerta, M; Tarazona, N; Roda, D; Cervantes, A; Castillo, J |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista1053
Data di pubblicazione
- 2020 - 202453
- 2010 - 2019413
- 2000 - 2009321
- 1990 - 1999208
- 1980 - 198957
- 1978 - 19791
Editore
- wiley blackwell1
Rivista
- HAEMATOLOGICA52
- DIGESTIVE AND LIVER DISEASE48
- JOURNAL OF ALLERGY AND CLINICAL I...45
- BLOOD39
- EUROPEAN JOURNAL OF NUCLEAR MEDIC...37
- JOURNAL OF PEDIATRIC GASTROENTERO...37
- ANNALS OF ONCOLOGY27
- RIVISTA DI STUDI POLITICI INTERNA...26
- BONE MARROW TRANSPLANTATION24
- SPORT SCIENCES FOR HEALTH21
Keyword
- pediatrics109
- Humans3
- Ring closure reactions3
- rinvenimenti monetali3
- Animals2
- autologous bone graft2
- Cardiovascular Diseases2
- Interventional2
- Medicinal chemistry2
- Pharmacology2
Lingua
- eng788
- ita72
- cze1
- fre1
Accesso al fulltext
- no fulltext1052
- open1